The world of biotech investing is always a difficult one. Often a binary event, such as a Food and Drug Administration (FDA) approval or a life-saving capital raise is the ... Read Full Story »
Biotech has strongly outperformed the S&P 500 since January of 2011. The NASDAQ Biotechnology Index (NBI) is up 90%, and the AMEX Biotechnology index (BTK) is up 50%, versus the ... Read Full Story »
Biotech stocks come and go as far as the flavor of the day for investors. While many of these companies are risky, and while many are too risky for many ... Read Full Story »
Investors and traders are usually on the hunt for new ideas that will generate positive returns or income. 24/7 Wall St. looks over numerous research calls to find great ideas ... Read Full Story »
24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the sector performed ... Read Full Story »
You know it is a bull market when you see major household names hitting 52-week highs. Right now we have many major stocks hitting fresh all-time highs! Should you be ... Read Full Story »
When companies start buying back their common stock on the open market, it can have multiple outcomes. It can offset employee stock option dilution, and it can lower the public ... Read Full Story »
Investing in biotech or biopharmaceutical stocks can prove to be a very daunting task. Many of the stocks have limited pipelines or their very survival depends on a single binary ... Read Full Story »
These are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Monday. AK Steel Holding Corp. (NYSE: AKS) cut to Sell at Goldman ... Read Full Story »
The week ahead will be the official flood gate opening for earnings season. We have a very large portion of the S&P 500 Index reporting fourth-quarter earnings, and we have many ... Read Full Story »
The dread and fear that can come with a cancer diagnosis have their roots in its killer nature. It is the number two cause of death in Americans, second only ... Read Full Story »
These are some of the top analyst upgrades, downgrades and initiations seen so far this Tuesday. There is a larger concentration around biotech and emerging pharma this morning, but that ... Read Full Story »
Big biotech had a stellar 2012. In 2013, though, the large biotech companies may be dwarfed in performance by the smaller players in the $1 billion to $5 billion range. ... Read Full Story »
U.S. equity markets opened lower this morning and remained down throughout the day. The likely reason for the downturn is lowered expectations for corporate earnings which will get off the ... Read Full Story »
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall St. research firms this Tuesday. Ameriprise Financial Inc. (NYSE: AMP) cut to Neutral at Credit Suisse. ... Read Full Story »